Valuation: CSL Limited

Capitalization 4.73TCr 4.02TCr 3.69TCr 3.5TCr 6.47TCr 4,37800Cr 6.6TCr 43TCr 17TCr 2,11900Cr 18TCr 17TCr 7,49900Cr P/E ratio 2026 *
35.5x
P/E ratio 2027 * 14.4x
Enterprise value 5.62TCr 4.78TCr 4.39TCr 4.16TCr 7.69TCr 5,20500Cr 7.85TCr 51TCr 20TCr 2,51900Cr 21TCr 21TCr 8,91600Cr EV / Sales 2026 *
3.56x
EV / Sales 2027 * 3.39x
Free-Float
99.9%
Yield 2026 *
2.99%
Yield 2027 * 3.27%
1 day-0.31%
1 week-2.21%
Current month-2.59%
1 month-2.51%
3 months-21.88%
6 months-37.75%
Current year-20.57%
1 week 135.91
Extreme 135.91
140.98
1 month 133.35
Extreme 133.35
144.99
Current year 133.35
Extreme 133.35
184.62
1 year 133.35
Extreme 133.35
275.79
3 years 133.35
Extreme 133.35
313.55
5 years 133.35
Extreme 133.35
319.78
10 years 91.62
Extreme 91.62
342.75
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Tech/Sci/R&D Officer 64 01/10/2020
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 14/08/2013
Director/Board Member 68 16/02/2016
Change 5d. change 1-year change 3-years change Capi.($)
-0.31%-2.21%-43.31%-54.50% 4.73TCr
+0.61%-2.25%+36.65%-9.50% 7.66TCr
+2.01%-2.91%+90.68%+200.91% 5.8TCr
-0.93%+60.10%+60.10%+60.10% 5.06TCr
+0.76%+0.14%+53.83%-38.45% 2.58TCr
-1.76%+4.76%+113.26%-65.81% 2.17TCr
+2.62%+0.89%+69.44%+31.30% 1.9TCr
+1.84%+4.73%+60.44%+55.93% 1.55TCr
-0.98%+1.63%+126.74%+420.69% 1.5TCr
-0.95%-1.08%-0.14%+595.82% 1.34TCr
Average +0.29%+1.10%+56.77%+119.65% 3.43TCr
Weighted average by Cap. +0.39%-0.33%+49.76%+72.09%

Financials

2026 *2027 *
Net sales 1.58TCr 1.34TCr 1.23TCr 1.17TCr 2.16TCr 1,46000Cr 2.2TCr 14TCr 5.67TCr 71TCr 5.92TCr 5.79TCr 2,50100Cr 1.64TCr 1.39TCr 1.28TCr 1.21TCr 2.24TCr 1,51600Cr 2.29TCr 15TCr 5.88TCr 73TCr 6.14TCr 6.01TCr 2,59700Cr
Net income 139.22Cr 118.37Cr 108.74Cr 103.02Cr 190.55Cr 13TCr 194.28Cr 1.28TCr 500.18Cr 6.24TCr 522.21Cr 511.22Cr 22TCr 330.34Cr 280.86Cr 258.03Cr 244.44Cr 452.14Cr 31TCr 460.98Cr 3.03TCr 1.19TCr 15TCr 1.24TCr 1.21TCr 52TCr
Net Debt 893.22Cr 759.43Cr 697.69Cr 660.96Cr 1.22TCr 83TCr 1.25TCr 8.18TCr 3.21TCr 40TCr 3.35TCr 3.28TCr 1,41600Cr 819.22Cr 696.52Cr 639.89Cr 606.2Cr 1.12TCr 76TCr 1.14TCr 7.5TCr 2.94TCr 37TCr 3.07TCr 3.01TCr 1,29900Cr
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.
Employees
29,904
Date Price Change Volume
17/26/17 137.13 $ -0.31% 15,42,554
16/26/16 137.55 $ -1.36% 13,49,509
15/26/15 139.44 $ +0.98% 6,57,099
14/26/14 138.08 $ +0.58% 7,72,145
13/26/13 137.29 $ -1.37% 10,76,257
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
98.57USD
Average target price
141.95USD
Spread / Average Target
+44.00%

Quarterly revenue - Rate of surprise